Screener
Immunovant, Inc. IMVT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Current portion of operating lease liabilities | 72 | 98 |
| Due to Roivant Sciences Ltd. | 175 | 273 |
| Total current liabilities | 104,422 | 68,775 |
| Total liabilities | 104,422 | 68,775 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
| Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2026 and March 31, 2025 | — | — |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s total liabilities?
- Immunovant, Inc. (IMVT) reported total liabilities of $104.42M in Q1 2026.
- How has Immunovant, Inc.'s total liabilities changed year-over-year?
- Immunovant, Inc.'s total liabilities increased by 51.8% year-over-year, from $68.78M to $104.42M.
- What is the long-term trend for Immunovant, Inc.'s total liabilities?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total liabilities has grown at a 37.8% compound annual growth rate (CAGR), from $21.01M to $104.42M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Immunovant, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude